Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Rekanemab NHI drug price listing Eisai press conference

Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo

E

Anti-Alzheimer's drug lecanemab

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.

E

Anti-Alzheimer's drug lecanemab

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

Eisai CEO Naito

Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., speaks during a press conference in Tokyo on July 7, 2023, after the U.S. Food and Drug Administration granted full approval for Eisai and Biogen Inc.'s anti-Alzheimer's drug lecanemab.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

E

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

E

Bell tower of todaiji temple

The location is the east side of the Daibutsu hall. The present building was built through donations collected by Todaiji Temple and rebuilt by Eisai during the Shogen years (1207-11). The style is a mixture of Indian and Chinese styles, in Irimoya style with tiled roofs.==Date:unknown, Place:Nara, Photo:unknown, (Credit:Nagasaki University Library/Kyodo News Images) [Cabinet Number30‐2‐0]